Systemic Analysis of PPARγ in Mouse Macrophage Populations Reveals Marked Diversity in Expression with Critical Roles in Resolution of Inflammation and Airway Immunity
暂无分享,去创建一个
M. Merad | G. Marcelin | N. Van Rooijen | G. Randolph | M. Greter | M. Leboeuf | E. Gautier | C. Jakubzick | R. Spanbroek | A. Habenicht | A. Chow | M. Bogunovic
[1] D. Rader,et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. , 2011, The Journal of clinical investigation.
[2] E. Gulbins,et al. CFTR-dependent susceptibility of the cystic fibrosis-host to Pseudomonas aeruginosa. , 2010, International journal of medical microbiology : IJMM.
[3] D. Riches,et al. PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. , 2010, Blood.
[4] R. Evans,et al. STAT6 Transcription Factor Is a Facilitator of the Nuclear Receptor PPARγ-Regulated Gene Expression in Macrophages and Dendritic Cells , 2010, Immunity.
[5] F. Ginhoux,et al. Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.
[6] R. Steinman,et al. Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas , 2010, Cell.
[7] C. Serhan. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? , 2010, The American journal of pathology.
[8] A. Remaley,et al. ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. , 2010, American journal of respiratory and critical care medicine.
[9] B. Barna,et al. Targeted PPARγ deficiency in alveolar macrophages disrupts surfactant catabolism , 2010, Journal of Lipid Research.
[10] B. Barna,et al. Targeted PPAR³ Deficiency In Alveolar Macrophages Disrupts Surfactant Catabolism , 2010, ATS 2010.
[11] C. Glass,et al. Pharmacological correction of a defect in PPARγ signaling ameliorates disease severity in Cftr-deficient mice , 2010, Nature Medicine.
[12] Leonore A. Herzenberg,et al. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets , 2010, Proceedings of the National Academy of Sciences.
[13] F. Tacke,et al. Comparison of gene expression profiles between human and mouse monocyte subsets. , 2010, Blood.
[14] F. Ginhoux,et al. Origin of the lamina propria dendritic cell network. , 2009, Immunity.
[15] L. Nagy,et al. The many faces of PPARgamma: anti-inflammatory by any means? , 2008, Immunobiology.
[16] D. Koller,et al. The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.
[17] C. Farver,et al. Peroxisome Proliferator-Activated Receptor-γ Regulates the Expression of Alveolar Macrophage Macrophage Colony-Stimulating Factor , 2008, The Journal of Immunology.
[18] Peter Tontonoz,et al. Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.
[19] V. Villella,et al. Tissue Transglutaminase Activation Modulates Inflammation in Cystic Fibrosis via PPARγ Down-Regulation1 , 2008, The Journal of Immunology.
[20] E. Gautier,et al. Enhanced Immune System Activation and Arterial Inflammation Accelerates Atherosclerosis in Lupus-Prone Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[21] Frank Brombacher,et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance , 2007, Nature.
[22] C. Glass,et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. , 2007, The Journal of clinical investigation.
[23] N. Van Rooijen,et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis , 2007, The Journal of experimental medicine.
[24] K. Morimura,et al. Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[25] F. Tacke,et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.
[26] F. Ginhoux,et al. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery , 2006, The Journal of experimental medicine.
[27] C. Knudson,et al. The Scaffolding Protein CG-NAP/AKAP450 Is a Critical Integrating Component of the LFA-1-Induced Signaling Complex in Migratory T Cells1 , 2005, The Journal of Immunology.
[28] M. Linton,et al. Conditional Knockout of Macrophage PPARγ Increases Atherosclerosis in C57BL/6 and Low-Density Lipoprotein Receptor–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[29] F. Tacke,et al. Role of CCR8 and Other Chemokine Pathways in the Migration of Monocyte-derived Dendritic Cells to Lymph Nodes , 2004, The Journal of experimental medicine.
[30] A. Ferrando,et al. Decreased expression of peroxisome proliferator activated receptor γ in CFTR−/− mice , 2004 .
[31] Steffen Jung,et al. Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.
[32] Dallas Jones,et al. Emerging roles of PPARS in inflammation and immunity , 2002, Nature Reviews Immunology.
[33] Andrew C. Li,et al. Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .
[34] M. Lazar,et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.
[35] T. Willson,et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.
[36] J. Whitsett,et al. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. , 1999, The Journal of clinical investigation.
[37] B. Seed,et al. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.
[38] Christopher K. Glass,et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.
[39] L. Hamann,et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.
[40] C. Haslett,et al. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. , 1996, Journal of immunology.
[41] N. Van Rooijen,et al. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.
[42] B. Barna,et al. Restoration of PPARγ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. , 2011, American journal of physiology. Lung cellular and molecular physiology.
[43] Pediatric Cardiology,et al. Pulmonary , 2010, Laboratory Investigation.
[44] Christopher K. Glass,et al. Combinatorial roles of nuclear receptors in inflammation and immunity , 2006, Nature Reviews Immunology.
[45] R. Evans,et al. A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .
[46] D. Altshuler,et al. The role of PPAR-γ in macrophage differentiation and cholesterol uptake , 2001, Nature Medicine.
[47] E. Varpela,et al. [Pulmonary alveolar proteinosis]. , 1966, Duodecim; laaketieteellinen aikakauskirja.